LRMR trades 227.9% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LRMR achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Larimar Therapeutics, Inc. (LRMR) has a Wall Street consensus price target of $12.00, based on estimates from 8 covering analysts. With the stock currently trading at $3.66, this represents a potential upside of +227.9%. The company has a market capitalization of $313M.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LRMR trades at a trailing P/E of -1.6x. Analysts expect EPS to grow +14.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.32 | $33.67 | +33.0% | Buy | 65.1x | 37 |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
PTCTPTC Therapeutics, Inc. | $7.0B | $84.43 | $95.83 | +13.5% | Buy | 95.3x | 26 |
FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
RAREUltragenyx Pharmaceutical Inc. | $3.0B | $30.77 | $48.36 | +57.2% | Buy | — | 33 |
AVNSAvanos Medical, Inc. | $1.2B | $24.95 | $23.00 | -7.8% | Hold | 24.9x | 8 |
MNKDMannKind Corporation | $1.3B | $4.14 | $8.50 | +105.3% | Buy | — | 19 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
CRLCharles River Laboratories International, Inc. | $10.4B | $215.75 | $214.14 | -0.7% | Buy | 19.4x | 37 |
IQVIQVIA Holdings Inc. | $32.4B | $191.14 | $219.44 | +14.8% | Buy | 14.9x | 44 |
Quick answers to the most common questions about buying LRMR stock.
The consensus Wall Street price target for LRMR is $12, representing 227.9% upside from the current price of $3.66. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LRMR has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 227.9% upside from current levels.
LRMR's current price is $3.66 with a consensus target of $12 (227.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for LRMR, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
LRMR is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LRMR stock forecast based on 8 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on LRMR, with a "Buy" consensus rating and $12 price target (227.9% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LRMR analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.